Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications
MF59<sup>®</sup>-adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose trivalent inactivated influenza vaccine (HD-IIV3) elicit an enhanced immune response in older adults compared to standard, quadrivalent inactivated influenza vaccines (IIV4). We sought to determine...
Main Authors: | Constantina Boikos, Mahrukh Imran, Van Hung Nguyen, Thierry Ducruet, Gregg C. Sylvester, James A. Mansi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/8/862 |
Similar Items
-
Development of MF-59 adjuvant using chitosan derivatives to influenza vaccine
by: Alireza Loghmani, et al.
Published: (2020-06-01) -
MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico
by: Aurelio Cruz-Valdez, et al.
Published: (2018-02-01) -
The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
by: Michele A. Kohli, et al.
Published: (2022-08-01) -
Pharmacoeconomic evaluation of influenza vaccination programs in elderly in Italy
by: Sergio Iannazzo, et al.
Published: (2009-06-01) -
Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence
by: Ilaria Loperto, et al.
Published: (2019-05-01)